Hardman & Co Research: Investing for growth

Hardman & Co Research: Investing for growth

Investing for growth: Abzena is a global life sciences group offering a broad range of integrated services and technologies to enable the development of better biopharmaceutical drugs. The company has an integrated fee-for-service offering which also provides an opportunity to embed its technology, 'Abzena Inside', into commercial drugs that could generate a long-term royalty stream. ABZA is investing for the future in state-of-the-art facilities in both Cambridge (UK) and San Diego (US) and in new equipment. These investments will drive ABZA along the path to profitability and cashflow breakeven. Trial news due from Gilead might be the catalyst for a re-rating.

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/abzena-plc-documents/23.02.18-investing-for-growth.pdf

About Hardman & Co: For the past 21 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.